Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full ...

Looking to add to their infield depth, the New York Mets agreed to a one-year deal with veteran Nick Madrigal on Friday, league sources confirmed. The New York Post first reported the agreement.

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results. CEO Bill Sibold hailed 2024 as a ...

CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...

Could this spell the end of Candelita in Queens? OMG. The New York Mets have signed versatile infielder Nick Madrigal to a split one-year contract worth differing amounts in the majors and minors ...

NEW YORK (AP) — The New York Mets signed infielder Nick Madrigal to a one-year contract Friday. Madrigal hit .221 with 10 RBIs in 51 games for the Chicago Cubs last year. He was non-tendered by ...

Investor expectations may be too high, however. Madrigal unveiled those figures Monday morning. The company said that its preliminary results indicated it earned $100 million to $103 million in ...

Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from ...